目的 评价醋酸甲羟孕酮联合化疗(多西他赛+卡铂)治疗转移性乳腺癌的疗效和毒副反应.方法 将60例转移性乳腺癌患者完全随机分为MTC组(n=30)和TC组(n=30).MTC组应用MTC方案,具体为:醋酸甲羟孕酮0.25 g,口服,2次/d,d1～21；多西他赛75 mg/m2,d1,卡铂AUC 5(300～400 mg/m2),d2,静脉滴注,21 d为1个周期.TC组应用TC方案,具体为:多西他赛75 mg/m2,d1；卡铂AUC 5 (300～400 mg/m2),d2,静脉滴注,21 d为1个周期.2组患者均治疗6个周期.结果 MTC组:CR 10例,PR16例,SD 4例,PD 0例,总有效率86.7％；TC组:CR 7例,PR 12例,SD 9例,PD 2例,总有效率63.3％,2组差异有统计学意义(P ＜0.05)；MTC组1年生存率90.0％(27/30),TC组1年生存率66.7％(20/30),2组差异有统计学意义(P＜0.05)；MTC组Ⅲ、Ⅳ度白细胞下降率为13.3％,食量增加80.0％(24/30),体重增加86.7％(26/30),KPS评分增加占66.7％(20/30),TC组Ⅲ、Ⅳ度白细胞下降率为36.7％,食量增加6.7％(2/30),体重增加16.7％(5/30),KPS评分增加占20％(6/30).结论 醋酸甲羟孕酮联合化疗(多西他赛+卡铂)治疗转移性乳腺癌可使治疗有效率进一步提高,患者生存率延长,毒副反应明显减轻.
目的 評價醋痠甲羥孕酮聯閤化療(多西他賽+卡鉑)治療轉移性乳腺癌的療效和毒副反應.方法 將60例轉移性乳腺癌患者完全隨機分為MTC組(n=30)和TC組(n=30).MTC組應用MTC方案,具體為:醋痠甲羥孕酮0.25 g,口服,2次/d,d1～21；多西他賽75 mg/m2,d1,卡鉑AUC 5(300～400 mg/m2),d2,靜脈滴註,21 d為1箇週期.TC組應用TC方案,具體為:多西他賽75 mg/m2,d1；卡鉑AUC 5 (300～400 mg/m2),d2,靜脈滴註,21 d為1箇週期.2組患者均治療6箇週期.結果 MTC組:CR 10例,PR16例,SD 4例,PD 0例,總有效率86.7％；TC組:CR 7例,PR 12例,SD 9例,PD 2例,總有效率63.3％,2組差異有統計學意義(P ＜0.05)；MTC組1年生存率90.0％(27/30),TC組1年生存率66.7％(20/30),2組差異有統計學意義(P＜0.05)；MTC組Ⅲ、Ⅳ度白細胞下降率為13.3％,食量增加80.0％(24/30),體重增加86.7％(26/30),KPS評分增加佔66.7％(20/30),TC組Ⅲ、Ⅳ度白細胞下降率為36.7％,食量增加6.7％(2/30),體重增加16.7％(5/30),KPS評分增加佔20％(6/30).結論 醋痠甲羥孕酮聯閤化療(多西他賽+卡鉑)治療轉移性乳腺癌可使治療有效率進一步提高,患者生存率延長,毒副反應明顯減輕.
목적 평개작산갑간잉동연합화료(다서타새+잡박)치료전이성유선암적료효화독부반응.방법 장60례전이성유선암환자완전수궤분위MTC조(n=30)화TC조(n=30).MTC조응용MTC방안,구체위:작산갑간잉동0.25 g,구복,2차/d,d1～21；다서타새75 mg/m2,d1,잡박AUC 5(300～400 mg/m2),d2,정맥적주,21 d위1개주기.TC조응용TC방안,구체위:다서타새75 mg/m2,d1；잡박AUC 5 (300～400 mg/m2),d2,정맥적주,21 d위1개주기.2조환자균치료6개주기.결과 MTC조:CR 10례,PR16례,SD 4례,PD 0례,총유효솔86.7％；TC조:CR 7례,PR 12례,SD 9례,PD 2례,총유효솔63.3％,2조차이유통계학의의(P ＜0.05)；MTC조1년생존솔90.0％(27/30),TC조1년생존솔66.7％(20/30),2조차이유통계학의의(P＜0.05)；MTC조Ⅲ、Ⅳ도백세포하강솔위13.3％,식량증가80.0％(24/30),체중증가86.7％(26/30),KPS평분증가점66.7％(20/30),TC조Ⅲ、Ⅳ도백세포하강솔위36.7％,식량증가6.7％(2/30),체중증가16.7％(5/30),KPS평분증가점20％(6/30).결론 작산갑간잉동연합화료(다서타새+잡박)치료전이성유선암가사치료유효솔진일보제고,환자생존솔연장,독부반응명현감경.
Objective To evaluate the efficiency toxicity of medroxyprogesterone acetate combined with chemotherapy ( docetaxel + carboplatin) therapy for metastatic breast cancer.Methods Sixty patients with metastatic breast cancer were randomly divided into MTC group ( n =30) and TC group ( n =30 ).MTC group applied MTC scheme,in particular:medroxyprogesterone acetate 0.5,po,bid,d1-21,docetaxel 75 mg/m2,d1,carboplatin AUC 5 (300-400 mg/m2 ),d2,Intravenous drip,21 days for a cycle; TC group applied TC scheme,in particular:docetaxel 75 mg/m2,dl,carboplatin AUC 5 (300-400 mg/m2 ),d2,intravenous drip,21 days for a cycle.Every patients were cured six cycle.Results MTC group:CR10 cases,PR16 cases,SD4 cases,PD0 case,the total effective rate was 86.7％ ; TC Group:CR7 cases,PR12 cases,SD9 cases,PD2 cases,total effective rate was 63.3％,a significant difference between the two groups(P ＜0.05) ; MTC group one year survival rate was 90.0％ (27/30),TC group one year survival rate was 66.7 ％ (20/30).There were significant differences between the two groups (P ＜ 0.05 ) ; MTC group Ⅲ,Ⅳ leukocytes reduce accounted for 13.3 ％,increased food intake accounted for 80.0％ (24/30),weight gain accounted for 86.7％ (26/30),KPS score increase accounted for 66.7％ (20/30),TC group Ⅲ,Ⅳ leukocytes reduce accounted for 36.7％,increased food intake accounted for 6.7％ (2/30),weight gain accounted for 16.7％ (5/30),KPS score increase accounted for 20％ (6/30).Conclusion Medroxyprogesterone acetate combined with chemotherapy( docetaxel + carboplatin) therapy for metastatic breast cancer to further improve efficiency and prolong survival,toxicity was significantly reduced.
